StockData
AstraZeneca PLC logo

AstraZeneca PLC

AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)

Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%

AstraZeneca Koselugo (selumetinib) by Quarter

Koselugo (selumetinib) — Emerging Markets product sales ($M) ($M)

QuarterlyAnnual

AstraZeneca Koselugo (selumetinib): $54M in Q2 2026, up 50.0% from a year earlier.

Latest, Q2 2026
54
Period ended Jun 30, 2026
Change on a year earlier
+50.0%
36 in Q2 2025
History
23 quarters
Since Q4 2020
Sources
23
Documents cited below

Where the Q2 2026 figure comes from

“|| Koselugo | 177 | | 29 | | 27 | | 52 | | - | | 54 | | 51 | | 45 | | 50 | | 34 | | 27 | | 21 | | 78 | | 90”

Source: Form 6-K FY2026Q2 Earnings Release ↗

Reported in Form 6-K / 20-F Product Sales Table.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedKoselugo (selumetinib) — Emerging Markets product sales ($M) ($M)Year on yearSource
Q2 2026Jun 30, 202654+50.0%Form 6-K FY2026Q2 Earnings Release ↗
Q1 2026Mar 31, 202661+52.5%Form 6-K FY2026Q1 Earnings Release ↗
Q4 2025Dec 31, 202539-43.5%Form 6-K FY2025Q4 Earnings Release ↗
Q3 2025Sep 30, 2025113+352.0%Form 6-K FY2025Q3 Earnings Release ↗
Q2 2025Jun 30, 202536+50.0%Form 6-K FY2025Q2 Earnings Release ↗
Q1 2025Mar 31, 202540-32.2%Form 6-K FY2025Q1 Earnings Release ↗
Q4 2024Dec 31, 202469+590.0%Form 6-K FY2024Q4 Earnings Release ↗
Q3 2024Sep 30, 202425+127.3%Form 6-K FY2024Q3 Earnings Release ↗
Q2 2024Jun 30, 202424+71.4%Form 6-K FY2024Q2 Earnings Release ↗
Q1 2024Mar 31, 202459+145.8%Form 6-K FY2024Q1 Earnings Release ↗
Q4 2023Dec 31, 202310+233.3%Form 6-K FY2023Q4 Earnings Release ↗
Q3 2023Sep 30, 202311+57.1%Form 6-K FY2023Q3 Earnings Release ↗
Q2 2023Jun 30, 202314+40.0%Form 6-K FY2023Q2 Earnings Release ↗
Q1 2023Mar 31, 202324+380.0%Form 6-K FY2023Q1 Earnings Release ↗
Q4 2022Dec 31, 20223–Form 6-K FY2022Q4 Earnings Release ↗
Q3 2022Sep 30, 20227–Form 6-K FY2022Q3 Earnings Release ↗

Breakdown

What makes up koselugo (selumetinib)

Cite this data

StockData. (2026). AstraZeneca Koselugo (selumetinib) ($M), quarterly Q4 2020–Q2 2026 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/med-koselugo-em

See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.